2018 Q1 Form 10-Q Financial Statement
#000114420418027804 Filed on May 14, 2018
Income Statement
| Concept | 2018 Q1 | 2017 Q1 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| YoY Change | ||
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $1.330M | $830.0K |
| YoY Change | 60.24% | 0.0% |
| % of Gross Profit | ||
| Research & Development | $977.0K | $941.0K |
| YoY Change | 3.83% | -4.95% |
| % of Gross Profit | ||
| Depreciation & Amortization | $25.00K | $16.00K |
| YoY Change | 56.25% | 0.0% |
| % of Gross Profit | ||
| Operating Expenses | $977.0K | $941.0K |
| YoY Change | 3.83% | -48.01% |
| Operating Profit | -$2.307M | -$1.770M |
| YoY Change | 30.34% | -2.32% |
| Interest Expense | ||
| YoY Change | ||
| % of Operating Profit | ||
| Other Income/Expense, Net | $10.00K | -$20.00K |
| YoY Change | -150.0% | -200.0% |
| Pretax Income | -$2.300M | -$1.790M |
| YoY Change | 28.49% | 0.0% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$2.298M | -$1.790M |
| YoY Change | 28.38% | 0.0% |
| Net Earnings / Revenue | ||
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$120.7K | -$95.77K |
| COMMON SHARES | ||
| Basic Shares Outstanding | ||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2018 Q1 | 2017 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $5.610M | $8.350M |
| YoY Change | -32.81% | -35.52% |
| Cash & Equivalents | $3.246M | $604.0K |
| Short-Term Investments | $2.360M | $7.740M |
| Other Short-Term Assets | $1.140M | $180.0K |
| YoY Change | 533.33% | 125.0% |
| Inventory | ||
| Prepaid Expenses | $1.103M | |
| Receivables | $1.120M | $200.0K |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $7.870M | $8.730M |
| YoY Change | -9.85% | -35.38% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $410.0K | $280.0K |
| YoY Change | 46.43% | -0.36% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $1.140M | $30.00K |
| YoY Change | 3700.0% | -90.13% |
| Total Long-Term Assets | $1.540M | $300.0K |
| YoY Change | 413.33% | -1.32% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $7.870M | $8.730M |
| Total Long-Term Assets | $1.540M | $300.0K |
| Total Assets | $9.410M | $9.030M |
| YoY Change | 4.21% | -34.63% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $3.260M | $360.0K |
| YoY Change | 805.56% | 28.11% |
| Accrued Expenses | $440.0K | $90.00K |
| YoY Change | 388.89% | -86.67% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $5.580M | $789.0K |
| YoY Change | 607.22% | -36.47% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | ||
| YoY Change | ||
| Total Long-Term Liabilities | $0.00 | $0.00 |
| YoY Change | ||
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $5.580M | $789.0K |
| Total Long-Term Liabilities | $0.00 | $0.00 |
| Total Liabilities | $5.579M | $790.0K |
| YoY Change | 606.2% | -36.29% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$76.91M | |
| YoY Change | 6.92% | |
| Common Stock | $85.15M | |
| YoY Change | 774000.0% | |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $3.830M | $8.243M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $9.410M | $9.032M |
| YoY Change | 4.19% | -34.6% |
Cashflow Statement
| Concept | 2018 Q1 | 2017 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$2.298M | -$1.790M |
| YoY Change | 28.38% | 0.0% |
| Depreciation, Depletion And Amortization | $25.00K | $16.00K |
| YoY Change | 56.25% | 0.0% |
| Cash From Operating Activities | -$2.126M | -$1.640M |
| YoY Change | 29.63% | -44.97% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $45.00K | $0.00 |
| YoY Change | -100.0% | |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $2.910M | $1.700M |
| YoY Change | 71.18% | -64.51% |
| Cash From Investing Activities | $2.864M | $1.699M |
| YoY Change | 68.57% | -64.38% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 25.00K | $0.00 |
| YoY Change | ||
| NET CHANGE | ||
| Cash From Operating Activities | -2.126M | -1.640M |
| Cash From Investing Activities | 2.864M | $1.699M |
| Cash From Financing Activities | 25.00K | $0.00 |
| Net Change In Cash | 763.0K | $1.699M |
| YoY Change | -55.09% | -5.08% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$2.126M | -$1.640M |
| Capital Expenditures | $45.00K | $0.00 |
| Free Cash Flow | -$2.171M | -$1.640M |
| YoY Change | 32.38% | -45.44% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2018Q1 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
46600000 | USD |
| CY2017Q4 | us-gaap |
Liabilities
Liabilities
|
5543000 | USD |
| CY2017Q4 | bcli |
Deferred Grant Income
DeferredGrantIncome
|
2625000 | USD |
| CY2018Q1 | bcli |
Deferred Grant Income
DeferredGrantIncome
|
1202000 | USD |
| CY2018Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
227000 | USD |
| CY2018Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
25000 | USD |
| CY2018Q1 | us-gaap |
Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
|
0 | USD |
| CY2018Q1 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-0.12 | |
| CY2018Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
19047350 | shares |
| CY2018Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2307000 | USD |
| CY2017Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
941000 | USD |
| CY2017Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
829000 | USD |
| CY2017Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-1770000 | USD |
| CY2017Q1 | bcli |
Financial Expenses Income Net
FinancialExpensesIncomeNet
|
15000 | USD |
| CY2018Q1 | us-gaap |
Depreciation
Depreciation
|
25000 | USD |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-2126000 | USD |
| CY2018Q1 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
227000 | USD |
| CY2018Q1 | bcli |
Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
|
116000 | USD |
| CY2018Q1 | us-gaap |
Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
|
-378000 | USD |
| CY2017Q1 | us-gaap |
Depreciation
Depreciation
|
16000 | USD |
| CY2017Q1 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
126000 | USD |
| CY2017Q1 | us-gaap |
Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
|
-92000 | USD |
| CY2017Q1 | bcli |
Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
|
-76000 | USD |
| CY2018Q1 | us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
1837000 | USD |
| CY2017Q1 | us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
17000 | USD |
| CY2018Q1 | bcli |
Increase Decrease In Deferred Grant Income
IncreaseDecreaseInDeferredGrantIncome
|
-1423000 | USD |
| CY2017Q1 | bcli |
Increase Decrease In Deferred Grant Income
IncreaseDecreaseInDeferredGrantIncome
|
0 | USD |
| CY2018Q1 | us-gaap |
Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
|
-2914000 | USD |
| CY2018Q1 | bcli |
Investment In Lease Deposit
InvestmentInLeaseDeposit
|
5000 | USD |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
2864000 | USD |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
25000 | USD |
| CY2018Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
763000 | USD |
| CY2017Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
0 | USD |
| CY2017Q1 | us-gaap |
Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
|
-1700000 | USD |
| CY2017Q1 | bcli |
Investment In Lease Deposit
InvestmentInLeaseDeposit
|
1000 | USD |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
1699000 | USD |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
0 | USD |
| CY2017Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
57000 | USD |
| CY2017Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
604000 | USD |
| CY2018Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
25000 | USD |
| CY2017Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
0 | USD |
| CY2018Q1 | bcli |
Percentage Of Royalty Paymentif Licensed Product Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentifLicensedProductCoveredByValidClaimOrOrphanDrugStatus
|
0.05 | pure |
| CY2018Q1 | bcli |
Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus
|
0.03 | pure |
| CY2018Q1 | us-gaap |
Maturity Of Time Deposits
MaturityOfTimeDeposits
|
P7M | |
| CY2018Q1 | us-gaap |
Liabilities
Liabilities
|
5579000 | USD |
| CY2018Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.00005 | |
| CY2017Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.00005 | |
| CY2018Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2017Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2018Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
19111326 | shares |
| CY2018Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
19111326 | shares |
| CY2017Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
18976169 | shares |
| CY2017Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
18976169 | shares |
| CY2017 | bcli |
Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
|
105000 | USD |
| CY2017 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4952000 | USD |
| CY2016Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
9902000 | USD |
| CY2017 | us-gaap |
Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
|
62000 | USD |
| CY2017 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
554000 | USD |
| CY2017 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
209000 | USD |
| CY2017 | us-gaap |
Maturity Of Time Deposits
MaturityOfTimeDeposits
|
P7M | |
| CY2017Q3 | us-gaap |
Grants Receivable
GrantsReceivable
|
15912000 | USD |
| CY2017Q3 | us-gaap |
Proceeds From Grantors
ProceedsFromGrantors
|
7050000 | USD |
| CY2017 | us-gaap |
Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
|
4425000 | USD |
| CY2018Q1 | us-gaap |
Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
|
1424000 | USD |
| CY2017Q4 | us-gaap |
Proceeds From Grantors
ProceedsFromGrantors
|
7050000 | USD |
| CY2018Q1 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
1103000 | USD |
| CY2018Q1 | us-gaap |
Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
|
1103000 | USD |
| CY2018Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
227000 | USD |
| CY2017Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
126000 | USD |
| CY2018Q1 | bcli |
Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status
ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus
|
P15Y | |
| CY2018Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>D.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Use of estimates</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: bold 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0px; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-WEIGHT: normal">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2017Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
1103000 | USD |
| CY2017Q4 | us-gaap |
Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
|
1378000 | USD |
| CY2018Q1 | us-gaap |
Proceeds From Grantors
ProceedsFromGrantors
|
9050 | USD |
